RxDoctor Payments DataLook up a doctor →

Arvind Krishna, MD

Endocrinology, Diabetes & Metabolism · Canton, OHNPI 1275579542

Payments from drug & device makers

$3,107,204in general payments, 2019–2025

Across 3,256 payments — averaging $954.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.7M
  • Novo Nordisk AS$606K
  • Amgen$206K
  • Genentech, Inc.$132K
  • Bayer$116K
  • Boehringer Ingelheim$110K
  • plus $269K from 47 others
$782in research payments, 2019–2025

Across 7 payments — averaging $111.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$782

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)431$1,668,726
Novo Nordisk AS2,424$606,092
Amgen(2 entities)18$205,989
Genentech, Inc.27$131,840
Bayer80$115,562
Boehringer Ingelheim10$109,930
F. Hoffmann-la Roche AG23$85,344
AstraZeneca(2 entities)6$82,187
Roche Diagnostics Operations, Inc.26$47,114
Biogen15$37,251
Amryt Pharma Holdings Ltd10$8,313
Chiasma, Inc.8$3,384
Insulet Corporation15$2,563
Novo Nordisk25$358
Corcept Therapeutics13$290
Abbott11$246
Lilly USA, LLC14$243
Sanofi-aventis U.S. LLC10$224
Dexcom, Inc.7$142
Xeris Pharmaceuticals, Inc.7$111
Novartis6$110
BETA Bionics, Inc.4$77
IBSA Pharma Inc.5$75
Ipsen Biopharmaceuticals, Inc3$67
Ascendis Pharma Endocrinology Inc3$63
Pfizer4$63
Radius Health, Inc.3$60
Tandem Diabetes Care, Inc.4$59
Nevro Corp.3$56
Amarin Pharma, Inc.4$51
Neurocrine Biosciences, Inc.2$48
Optos, Inc.2$46
Amneal Pharmaceuticals LLC3$45
Ultragenyx Pharmaceutical Inc.3$44
Recordati_rare_diseases_inc.3$37
Vivus LLC3$36
Amphastar Pharmaceuticals, Inc.2$34
Globus Medical1$33
Medtronic2$32
Esperion Therapeutics, Inc.2$32
Averitas Pharma Inc.1$26
Clarus Therapeutics Inc.2$25
Sequel Med Tech, LLC1$22
GRT US Holding, Inc.1$22
Soleno Therapeutics, Inc.1$21
Regeneron Healthcare Solutions, Inc.1$16
Antares Pharma, Inc.1$16
Currax Pharmaceuticals LLC1$15
Takeda Pharmaceuticals U.S.A., Inc.1$15
Boehringer Ingelheim International GmbH1$13
Merck1$12
Lifescan, Inc.1$12
Echosens North America, Inc.1$12

How this compares

$3,107,204 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio →

Medicare billing

Part B allowed, 2024
$230,511
Medicare patients
787
Services billed
11,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Canton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →